Cevipabulin
Modify Date: 2025-08-25 13:35:40
Cevipabulin structure
|
Common Name | Cevipabulin | ||
|---|---|---|---|---|
| CAS Number | 849550-05-6 | Molecular Weight | 464.820 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C18H18ClF5N6O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CevipabulinCevipabulin(TTI-237) is a novel, potent, synthetic small molecule, inhibits binding of vinblastine at the Vinca alkaloid site of the αβ-tubulin heterodimer.IC50 value: Target: Antimicrotubule agentin vitro: TTI-237 inhibited the binding of [(3)H]vinblastine to tubulin, but it caused a marked increase in turbidity development that more closely resembled the effect observed with docetaxel than that observed with vincristine. When applied to cultured human tumor cells at concentrations near its IC(50) value for cytotoxicity (34 nmol/L), TTI-237 induced multiple spindle poles and multinuclear cells, as did paclitaxel, but not vincristine or colchicine. Flow cytometry experiments revealed that, at low concentrations (20-40 nmol/L), TTI-237 produced sub-G(1) nuclei and, at concentrations above 50 nmol/L, it caused a strong G(2)-M block. The compound was a weak substrate of multidrug resistance 1 (multidrug resistance transporter or P-glycoprotein). In a cell line expressing a high level of P-glycoprotein, the IC(50) of TTI-237 increased 25-fold whereas those of paclitaxel and vincristine increased 806-fold and 925-fold, respectively. TTI-237 was not recognized by the MRP or MXR transporters [1]. TTI-237 inhibited the exchange of [(3)H]GTP at the exchangeable nucleotide site of the tubulin heterodimer, and was similar to vincristine in its effects on the phosphorylation of eight intracellular proteins in HeLa cells [3].in vivo: TTI-237 was active in vivo in several nude mouse xenograft models of human cancer, including LoVo human colon carcinoma and U87-MG human glioblastoma, when dosed i.v. or p.o [1]. |
| Name | 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine |
|---|---|
| Synonym | More Synonyms |
| Description | Cevipabulin(TTI-237) is a novel, potent, synthetic small molecule, inhibits binding of vinblastine at the Vinca alkaloid site of the αβ-tubulin heterodimer.IC50 value: Target: Antimicrotubule agentin vitro: TTI-237 inhibited the binding of [(3)H]vinblastine to tubulin, but it caused a marked increase in turbidity development that more closely resembled the effect observed with docetaxel than that observed with vincristine. When applied to cultured human tumor cells at concentrations near its IC(50) value for cytotoxicity (34 nmol/L), TTI-237 induced multiple spindle poles and multinuclear cells, as did paclitaxel, but not vincristine or colchicine. Flow cytometry experiments revealed that, at low concentrations (20-40 nmol/L), TTI-237 produced sub-G(1) nuclei and, at concentrations above 50 nmol/L, it caused a strong G(2)-M block. The compound was a weak substrate of multidrug resistance 1 (multidrug resistance transporter or P-glycoprotein). In a cell line expressing a high level of P-glycoprotein, the IC(50) of TTI-237 increased 25-fold whereas those of paclitaxel and vincristine increased 806-fold and 925-fold, respectively. TTI-237 was not recognized by the MRP or MXR transporters [1]. TTI-237 inhibited the exchange of [(3)H]GTP at the exchangeable nucleotide site of the tubulin heterodimer, and was similar to vincristine in its effects on the phosphorylation of eight intracellular proteins in HeLa cells [3].in vivo: TTI-237 was active in vivo in several nude mouse xenograft models of human cancer, including LoVo human colon carcinoma and U87-MG human glioblastoma, when dosed i.v. or p.o [1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C18H18ClF5N6O |
| Molecular Weight | 464.820 |
| Exact Mass | 464.115082 |
| PSA | 76.37000 |
| LogP | 3.94 |
| Index of Refraction | 1.588 |
| Storage condition | 2-8℃ |
|
~40%
Cevipabulin CAS#:849550-05-6 |
| Literature: Zhang, Nan; Ayral-Kaloustian, Semiramis; Nguyen, Thai; Afragola, Jay; Hernandez, Richard; Lucas, Judy; Gibbons, James; Beyer, Carl Journal of Medicinal Chemistry, 2007 , vol. 50, # 2 p. 319 - 327 |
|
~%
Cevipabulin CAS#:849550-05-6 |
| Literature: WO2005/30775 A1, ; Page/Page column 73-74 ; |
|
~%
Cevipabulin CAS#:849550-05-6 |
| Literature: Journal of Medicinal Chemistry, , vol. 50, # 2 p. 319 - 327 |
![(S)-5-chloro-6-(2,4,6-trifluorophenyl)-N-(1,1,1-trifluoropropan-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine structure](https://image.chemsrc.com/caspic/048/249648-16-6.png)
![5,7-dichloro-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine structure](https://image.chemsrc.com/caspic/110/214707-02-5.png)
| 5-Chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(2S)-1,1,1-trifluoro-2-propanyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine |
| TTI 237 |
| UNII-P14M0DWS2J |
| [1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]- |
| Cevipabulin |
| UNII:P14M0DWS2J |